Key Highlights

  • CYPH shares are trading down 0.53% at $1.86, versus a prior close of $1.87.
  • Earnings were $1.13 per share, versus a $0.03 market estimate.
  • Nine-month Net Income was $268.2 million, and results move with the ZEC price.
  • Mining began August 18 and held about 15% of ZCash network hashrate at quarter end.

Cypherpunk Technologies (NASDAQ:CYPH) shares are trading slightly lower today after the company reported third-quarter Earnings of $1.13 per share, far above the $0.03 market estimate. Net income for the nine months was $268.2 million, and cash and equivalents were $56.0 million.

The company formerly operated as Leap Therapeutics and changed its name in November 2025. It now pursues privacy technology through a Zcash treasury, a Mining operation and investments in privacy projects, while its biotechnology work continues through a subsidiary.

Results Move With the Zcash Price

The filing explains that the price of ZEC drives results through the Fair Value of an embedded derivative tied to its holdings. A higher ZEC price at the end of the fourth quarter than at September 30 would produce income, and a lower price a loss. Since October 1, ZEC has traded between below $1,000 and above $1,445.

The company has a $200 million sales agreement that, with its cash, it says should fund operating expenses for at least 12 months.

Mining Fleet and Privacy Investments Expand the Strategy

Mining began August 18, when the fleet represented about 18% of network hashrate, falling to about 15% at September 30 as the network grew. Hosting agreements charge $0.067 to $0.072 per kilowatt-hour, and machines are depreciated over three years.

In March the company invested $5.0 million in the Zcash Open Development Lab through a simple agreement for future equity. It also started a strategic process for sirexatamab, a cancer drug with Fast Track Designation and an agreed Phase 3 design for a DKK1-high colorectal cancer population.

Outlook: ZEC Price and the Sirexatamab Process Are the Next Tests

Results will keep swinging with ZEC valuations, and mining output is roughly proportional to the company's share of network hashrate. Investors will watch hashrate share, the outcome of the sirexatamab process and any expansion of the fleet.